RxDoctor Payments Data

Ulrich Berg, MD

Psychiatry · San Francisco, CANPI 1760400667

Payments from drug & device makers

$8,745in general payments, 2019–2025

Across 378 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Axsome Therapeutics, Inc.$2K
  • Lundbeck LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$737
  • Otsuka America Pharmaceutical, Inc.$659
  • plus $820 from 5 others

What the payments were for

  • Food & beverage$8,740100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,745 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$360,251
Medicare patients
103
Services billed
3,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole46$84,743
TrintellixVortioxetine Hydrobromide66$43,105
CaplytaLumateperone Tosylate12$24,629
Lurasidone Hcl18$11,467
Paliperidone ErPaliperidone33$10,275
Olanzapine OdtOlanzapine11$2,908
Aripiprazole72$2,872
Vilazodone Hcl19$2,247
Quetiapine Fumarate44$1,821
Bupropion XlBupropion Hcl93$1,700
Alprazolam91$1,496
Quetiapine Fumarate ErQuetiapine Fumarate12$1,156
Divalproex Sodium27$1,066
Methylphenidate Hcl30$1,021
Duloxetine Hcl53$920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$659$84,74346 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,156$43,10566 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$737$24,62912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →